APP and Alzheimer disease: Preclinical immunotherapy for AD in transgenic mice (Tg) showed the ability to reduce or abolish Aβ pathology by overexpressing a mutant Aβ precursor protein (AβPP) with Aβ42; this was first reported in 1999 [84].